Aptevo Therapeutics Inc. (APVO)
|52 Week Range||0.3-7.2|
|1y Target Est||-|
|DCF Unlevered||APVO DCF ->|
|DCF Levered||APVO LDCF ->|
|Debt / Equity||35.37%||Neutral|
Upgrades & Downgrades
Latest APVO news
7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes
30 July 2023
Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poo...
The Top 7 Growth Stocks in Biotech
3 March 2023
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Why Did Aptevo Therapeutics Stock Jump 25% Today?
24 March 2022
Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher Thursday after the company reported 2021 financial results. Aptevo said royalty revenue totaled $12.3 million in 2021, up from royalti...
Why Are Aptevo Therapeutics Shares Trading Higher Today?
9 February 2022
Aptevo Therapeutics Inc APVO earned a $10 million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Management...
Healthcare Stock Soars on Cancer Treatment Update
23 November 2021
The shares of Aptevo Therapeutics Inc (NASDAQ:APVO) are soaring today, up 35% to trade at $8.75 at last check, after the biotech concern announced that one high-risk cancer patient had a complete remi...
Aptevo Therapeutics (APVO) Stock: Why The Price Surged Today
23 November 2021
The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by over 40% during intraday trading today. This is why it happened.
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at ...
27 October 2021
SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology the...
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontier...
28 September 2021
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for ta...
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myel...
17 August 2021
Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was pu...
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
12 August 2021
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ther...